Bayer Aktiengesellschaft

Franz-Josef Van Der Staay

Joachim Schuhmacher

Bernard Schmidt

Rudolf Schohe-Loop

Achim Feurer

Peter-Rudolf Seidel

Richard J Fanelli

Georg Terstappen

Richard T McCarthy

William Bullock

Jane C Chisholm

Karl-Heinz Schlemmer

Hans-Georg Lerchen

Martin Hendrix

Bernd Riedl

Rudy Schreiber

Toshiya Moriwaki

Chantal F&uuml;rstner

Dagmar Schauss

Werner Schr&ouml;der

Frank B&ouml;ss

Delf Schmidt

Walter Hubsch

Rolf Grosser

Ulrich Niew&ouml;hner

Nagahiro Yoshida

Frank-Gerhard Böss

Maria Niewöhner, Legal Representative

Gerhard König

Wolfgang Roben

Gabriele Handke

Stephan Lensky

Jens-Kerim Erg&uuml;den

Frank-Gerhard B&ouml;ss

Gerhard K&ouml;nig

Jens Erg&uuml;den

Bernhard Schmidt

The invention relates to novel substituted imidazotriazinones, to a method for their production and to the use thereof for producing medicaments, in particular to improve perception, powers of concentration, learning capacity and/or memory retentiveness.

Substituted imidazotriazinones

The invention relates to novel 3-oxo-2,1-benzisomazol-1(3H)-carboxamides (I), where R , R are the same or different and independently&equals;H, halogen, C C alkyl C C alkoxy, C C perfluoroalkyl, or a group NR R ; R , R are the same or different and independently&equals;C C alkyl, whose carbon chain is optionally interrupted by an O, S or NR and is optionally singly or severally substituted by C C cycloalkyl, C C alkoxy, OH, halogen or NR R ; C C cycloalkyl whose carbon chain is optionally interrupted by an O, S or NR and is optionally singly or severally substituted by C C alkoxy, OH, halogen or NR R , or R and R together with a nitrogen atom form a saturated or partially unsaturated - to -membered mono- or bi-cyclic heteocycle, which, optionally, contains up to two further heteroatoms, from N, O or S and is, optionally, substituted by C C alkyl, C C alkoxy, OH, halogen, COOR or NR R and X&equals;O or S. The invention further relates to methods for production thereof and use thereof in the production of medicaments for the prophylaxis and/or treatment of diseases of the central nervous system, in particular, cognitive disorders, such as Alzheimer's disease and other forms of dementia, cerebral infarct, skull and brain trauma and pain.

3-oxo-2,1-benzisoxazol-1(3H)-carboxamides for treatment of CNS diseases

The present invention relates to new substituted imidazotriazinones, processes for their preparation, and their use for the production of medicaments, in particular for improving perception, concentration power, learning power and/or memory power.

The present invention relates to novel 2-aminocarbonyl-5(2H)-isoxazolones as selective ligands of a high-affinity binding site of diisopropyl fluorophosphate (DFP) on brain membranes for the prophylaxis and treatment of disorders of the central nervous system, in particular cognitive disorders, depression, schizophrenia and anxiety.

2-aminocarbonyl-5(2H)-isoxazolones as ligands of a DFP-binding site treatment of CNS-diseases

The present invention relates to bis-(quinolyl)-diamines of the general formula (I):

Bis-(quinolyl)-diamines

The present invention relates to 2,2'-bridged bis-2,4-diaminoquinazolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides processes for the preparation of the compounds of the formula (I), their use for the preparation of drugs, and drugs containing said compounds.

2,2'-bridged bis-2,4-diaminoquinazolines

The present invention relates to ring-bridged bis-quinolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides a process for the preparation of compounds of the formula (I), their use for the preparation of drugs, and drugs containing said compounds.

Ring-bridged bis-quinolines

4,4'-Bridged bis-2,4-diaminoquinazolines of the general formula (I) ##STR1## processes for their preparation and use as agents acting on the potassium channels of the brain.

4, 4'-bridged bis-2, 4-diaminoquinazolines

The present invention relates to the use of bisquinolines of the general formula ##STR1## in which the substituents mentioned have the meanings given in the description. The invention furthermore relates to new bisquinolines of the general formula (I), to a process for the preparation of the known and the new bisquinolines, to the use of the new bisquinolines as medicaments, to their use for the preparation of medicaments, and to medicaments comprising them.

Use of bisquinoline compounds in the treatment of cerebral disorders

The present invention provides 2,4'-bridged bis-2,4-diaminoquinazolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides a process for the preparation of the compounds of the formula (I), drugs containing said compounds and processes for the preparation of drugs containing said compounds.

2,4'-bridged bis-2,4-diaminoquinazolines

Growing community of inventors

Lohmar, Germany

Franz-Josef Van Der Staay